Sun Pharma CSR Spending Report of Rs 50.83 Crore for FY25

NEW DELHI (India CSR): In an era where corporate accountability extends far beyond financial metrics, Sun Pharmaceutical Industries Limited, India’s largest pharmaceutical company, has once again underscored its profound commitment to societal well-being. The company’s Annual Report for the financial year 2024-25 reveals a substantial investment in Corporate Social Responsibility (CSR) initiatives, demonstrating a holistic approach to enhancing global healthcare standards and improving lives. Guided by a keen sense of purpose, Sun Pharma’s journey has always been about making high-quality medicines more accessible, improving patient care, and driving better health outcomes for millions worldwide. This ethos is vividly reflected in their detailed CSR spending report for FY25.

Commitment to Sustainable Growth and Global Recognition

Sun Pharma’s dedication to responsible business practices is deeply embedded in its long-term strategy, encompassing decisive action across energy usage, emission reduction, water stewardship, waste management, ethical governance, and community well-being. This commitment has garnered global recognition, with Sun Pharma being included in the S&P Global Sustainability Yearbook 2025, ranking among the top 5% of pharmaceutical companies assessed by S&P globally for corporate sustainability. This achievement is a testament to the company’s efforts to integrate Environmental, Social, and Governance (ESG) principles into its operations. The company operates with a global footprint, serving over 100 countries and employing more than 43,000 people worldwide, embodying its mission to drive impact through access and innovation.

FY25 CSR Spending: A Comprehensive Overview

Category	Details
Company Name	Sun Pharmaceutical Industries Limited
Financial Year Covered	FY 2025 (ending March 31, 2025)
Total CSR Obligation	Rs 57.78 Crores
Total CSR Spent	Rs 50.83 Crores
– Direct Project Spending	Rs 48.33 Crores
– Administrative Overheads	Rs 2.43 Crores
– Impact Assessment	Rs 0.07 Crores (₹ 7 Lakhs)
Unspent Amount (FY25)	Rs 6.95 Crores
– Transferred to Unspent CSR Account	Rs 4.74 Crores
Employees (Global)	Over 43,000
Global Presence	Operations in 100+ countries
Flagship CSR Reach (Lives Touched)	Over 1 million

For the financial year ended March 31, 2025, Sun Pharma’s CSR efforts saw a significant allocation of funds. The total CSR obligation for the year stood at Rs 57.78 crores (` 577.8 Million), reflecting 2% of its average net profits from the preceding three financial years, as mandated by Section 135 of the Companies Act, 2013.

The total expenditure incurred on CSR activities during FY25 was Rs 50.83 crores (` 508.3 Million). This amount was strategically distributed across various initiatives:

Rs 48.33 crores (` 483.3 Million) was spent directly on CSR projects.
Rs 2.43 crores (` 24.3 Million) was allocated to administrative overheads.
Rs 7 lakhs (` 0.7 Million) was spent on impact assessment studies.

Despite these significant investments, a shortfall of Rs 6.95 crores (69.5 Million) was noted, with Rs 4.74 crores ( 47.4 Million) of unspent funds transferred to the Unspent CSR Account for ongoing projects. This unspent amount pertains primarily to two key ongoing projects, with reasons attributed to unforeseen circumstances and project dependencies.

Flagship Initiatives: Touching Lives at the Grassroots

Sun Pharma’s CSR programs are designed to create maximum impact by focusing on key areas such as healthcare, education, water & sanitation, rural development, and environmental conservation, aligning with the United Nations Sustainable Development Goals (UN SDGs). In FY25, these initiatives collectively touched over 1 million lives.

1. Mobile Healthcare Unit (MHU) Project: This vital initiative continues to be a cornerstone of Sun Pharma’s community healthcare efforts. The company operates 12 Mobile Healthcare Units that deliver primary healthcare and reproductive child health services to communities residing near its plant locations. These fully-equipped clinics-on-wheels provide consultations, medicines, and preventive healthcare awareness. In FY25, a portion of the allocated funds for this ongoing project, Rs 2.50 crores (` 25.0 Million), remained unutilized due to rescheduling of activities and dependencies on external stakeholders. An impact assessment confirmed the continued commitment of Sun Pharma, with an average year-on-year increase in spending on the MHU program of approximately 10%. The project has been instrumental in bridging healthcare gaps, especially where systemic issues like non-availability of MBBS doctors, medicine shortages, and staffing shortfalls plague traditional healthcare centers.

2. School Infrastructure Development Program: Addressing critical gaps in basic school infrastructure, this program aims to enhance the learning environment in government schools, particularly in underserved and rural areas. Implemented from FY2020-23, the program benefited 40,194 students across 21 schools in various locations in Gujarat (Panchmahal, Vadodara, Bharuch), Madhya Pradesh (Dewas), and Tamil Nadu (Chengalpattu). The project budget for this period was Rs 1.18 crores (` 1.18 Cr.). This initiative strongly aligns with National Education Policy (NEP) 2020 and Samagra Shiksha Abhiyan.

3. Setting up a Skilling Institute – PAGE Foundation: A forward-looking initiative, Sun Pharma collaborated with other member companies of the Indian Pharmaceutical Alliance (IPA) to establish the Pharmaceutical Academy for Global Excellence Foundation (PAGE Foundation). This skilling institute aims to develop talent for the pharmaceutical industry. The total estimated cost of this project is approximately Rs 200 crores (2,000 Million), with Sun Pharma and other participating members contributing equally. In FY25, Rs 4.74 crores ( 47.4 Million) allocated to this project remained unspent, primarily due to ongoing land acquisition processes in Hyderabad and Gujarat.

Holistic Approach to Sustainability

Beyond direct community spending, Sun Pharma integrates sustainability into its core long-term strategy. The company is actively working to combat climate change by improving energy efficiency, increasing renewable energy use, strengthening water conservation, and advancing sustainable waste management. Notably, renewable energy now constitutes 49.77% of its overall energy mix. Sun Pharma has already achieved a 24.69% reduction in absolute Scope 1 and Scope 2 carbon emissions against a target of 35% by 2030 (compared to a 2020 baseline), and has surpassed its target of a 10% reduction in water consumption by 2025, achieving a 31.70% reduction to date. The company also prioritizes human capital development, with a diversity target to achieve 30% women representation across its global workforce by 2040.

Outlook and Future Direction

Sun Pharma’s robust financial position, with a net cash position of approximately Rs 31,000 crores (US$ 3.1 Billion) as of March 31, 2025, enables it to continue exploring both organic and inorganic growth opportunities, including strengthening its Global Specialty portfolio. The company anticipates mid to high single-digit consolidated topline growth in FY26, with R&D spend expected to be in the range of 6%-8% of sales, indicating continued investment in innovation. Their unwavering focus on combating climate change and enhancing global healthcare standards through accessible, high-quality medicines remains paramount.

Sun Pharma’s CSR journey is akin to tending a garden; by diligently planting seeds of change through healthcare, education, and environmental stewardship, they cultivate a healthier, more equitable future for communities around the world. Each investment is a drop of water, fostering growth and bearing fruit that benefits millions.